

DAFTAR PUSTAKA

- [1] “2023 Alzheimer’s disease facts and figures,” *Alzheimer’s Dement.*, no. February, hal. 1598–1695, 2023, doi: 10.1002/alz.13016.
- [2] “Dementia,” *World Health Organization*, 2023. <https://www.who.int/news-room/fact-sheets/detail/dementia> (diakses 5 Juni 2023).
- [3] E. Nichols, J. D. Steinmetz, S. E. Vollset, K. Fukutaki, J. Chalek, F. Abd-Allah, A. Abdoli, A. Abualhasan, E. Abu-Gharbieh, T. T. Akram, H. Al Hamad, F. Alahdab, F. M. Alanezi, V. Alipour, S. Almustanyir, H. Amu, I. Ansari, J. Arabloo, T. Ashraf, *et al.*, “Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019,” *Lancet Public Heal.*, vol. 7, no. 2, hal. e105–e125, 2022, doi: 10.1016/S2468-2667(21)00249-8.
- [4] L. Mucke, “Neuroscience: Alzheimer’s disease,” *Nature*, vol. 461, no. 7266, hal. 895–897, 2009, doi: 10.1038/461895a.
- [5] L. A. Gomes, S. A. Hipp, A. Rijal Upadhaya, K. Balakrishnan, S. Ospitalieri, M. J. Koper, P. Largo-Barrientos, V. Uytterhoeven, J. Reichwald, S. Rabe, R. Vandenberghe, C. A. F. von Arnim, T. Tousseyn, R. Feederle, C. Giudici, M. Willem, M. Staufenbiel, dan D. R. Thal, “A β -induced acceleration of Alzheimer-related τ -pathology spreading and its association with prion protein,” *Acta Neuropathol.*, vol. 138, no. 6, hal. 913–941, 2019, doi: 10.1007/s00401-019-02053-5.
- [6] B. C. Uzuegbunam, D. Librizzi, dan B. H. Yousefi, *PET radiopharmaceuticals for Alzheimer’s disease and Parkinson’s disease diagnosis, the current and future landscape*, vol. 25, no. 4. 2020. doi: 10.3390/molecules25040977.
- [7] T. Guo, W. Noble, dan D. P. Hanger, “Roles of tau protein in health and disease,” *Acta Neuropathol.*, vol. 133, no. 5, hal. 665–704, 2017, doi: 10.1007/s00401-017-1707-9.
- [8] B. Marples, M. McGee, S. Callan, S. E. Bowen, B. J. Thibodeau, D. B. Michael, G. D. Wilson, M. E. Maddens, J. Fontanesi, dan A. A. Martinez, “Cranial irradiation significantly reduces beta amyloid plaques in the brain and improves cognition in a murine model of Alzheimer’s Disease (AD),” *Radiother. Oncol.*, vol. 118, no. 1, hal. 43–51, 2016, doi: 10.1016/j.radonc.2015.10.019.
- [9] J. M. Cuttler, E. R. Moore, V. D. Hosfeld, dan D. L. Nadolski, “Treatment of Alzheimer Disease With CT Scans : A Case Report,” *Dose-Response*, no. June, hal. 1–7, 2016, doi: 10.1177/1559325816640073.
- [10] J. M. Cuttler, E. R. Moore, V. D. Hosfeld, dan D. L. Nadolski, “Update on a patient with alzheimer disease treated with CT scans,” *Dose-Response*, vol. 15, no. 1, hal. 1–2, 2017, doi: 10.1177/1559325817693167.



- [11] J. M. Cuttler, E. R. Moore, V. D. Hosfeld, dan D. L. Nadolski, "Second Update on a Patient With Alzheimer Disease Treated by CT Scans," *Dose-Response*, vol. 16, no. 1, hal. 1–2, 2018, doi: 10.1177/1559325818756461.
- [12] "The Safety and Scientific Validity of Low-dose Whole Brain Radiotherapy in Alzheimer's Disease.," *ClinicalTrials.gov*. <https://clinicaltrials.gov/study/NCT04203121> (diakses 21 Juni 2021).
- [13] "Study of Low Dose Whole Brain Irradiation in the Treatment of Alzheimer's Disease.," *ClinicalTrials.gov*. <https://clinicaltrials.gov/study/NCT02359864> (diakses 21 Juni 2021).
- [14] "Low Dose RT to Reduce Cerebral Amyloidosis in Early Alzheimer's.," *ClinicalTrials.gov*. <https://clinicaltrials.gov/study/NCT02769000> (diakses 21 Juni 2021).
- [15] "Effect of Low Dose Radiotherapy on Brain Amyloidosis in the Treatment of Alzheimer's Disease ClinicalTrials.gov," *ClinicalTrials.gov*. <https://clinicaltrials.gov/study/NCT03352258> (diakses 21 Juni 2021).
- [16] "Nuclear Medicine," *National Institute of Health U.S. Department of Health & Human Service*. <https://www.nibib.nih.gov/science-education/science-topics/nuclear-medicine> (diakses 5 Juli 2023).
- [17] "Radioisotope Brief: Iodine-131 (I-131)," *CDC Radiation Emergencies*. <https://www.cdc.gov/nceh/radiation/emergencies/isotopes/iodine.htm> (diakses 5 Juli 2023).
- [18] R. Khurana, C. Coleman, C. Ionescu-Zanetti, S. A. Carter, V. Krishna, R. K. Grover, R. Roy, dan S. Singh, "Mechanism of thioflavin T binding to amyloid fibrils," *J. Struct. Biol.*, vol. 151, no. 3, hal. 229–238, 2005, doi: 10.1016/j.jsb.2005.06.006.
- [19] C. A. Mathis, B. J. Bacskai, S. T. Kajdasz, M. E. McLellan, M. P. Frosch, B. T. Hyman, D. P. Holt, Y. Wang, G. F. Huang, M. L. Debnath, dan W. E. Klunk, "A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain," *Bioorganic Med. Chem. Lett.*, vol. 12, no. 3, hal. 295–298, 2002, doi: 10.1016/S0960-894X(01)00734-X.
- [20] J. P. Pouget, C. Lozza, E. Deshayes, V. Boudousq, dan I. Navarro-Teulon, "Introduction to radiobiology of targeted radionuclide therapy," *Front. Med.*, vol. 2, no. MAR, hal. 12, 2015, doi: 10.3389/fmed.2015.00012.
- [21] G. B. Saha, *Fundamentals of Nuclear Pharmacy*, 5th ed. New York: Springer, 2003.
- [22] "Sulfur-35," *PubChem*. <https://pubchem.ncbi.nlm.nih.gov/compound/Sulfur-35> (diakses 19 Juli 2023).



- [23] C. Papastefanou, "Chlorine-39 in rainfall at a temperate latitude (40°N)," *J. Environ. Radioact.*, vol. 92, no. 3, hal. 175–182, 2007, doi: 10.1016/j.jenvrad.2006.11.005.
- [24] S. Eiji, "Development of techniques of production of sulfur-35 and its inorganic compounds," *Japan Atomic Energy Research*, 1981.
- [25] S. Y. Choi, N. H. Kwon, S. T. Kim, D. W. Kim, M. J. Chung, G. H. Jahng, dan W. Chung, "The Effect of Low Dose Radiation on Alzheimer's Disease-Induced TG Mice," *Int. J. Radiat. Oncol.*, vol. 102, no. 3, hal. e210–e211, 2018, doi: 10.1016/j.ijrobp.2018.07.738.
- [26] K. Ceyzériat, P. Millet, T. Zilli, G. B. Frisoni, V. Garibotto, dan B. Tournier, "Low-dose radiation therapy: A new potential treatment targeting amyloid load and neuroinflammation in an AD rat model," *Alzheimer's Dement.*, vol. 16, no. S2, hal. 1–2, 2020, doi: 10.1002/alz.042402.
- [27] S. Kim, Y. Nam, C. Kim, H. Lee, S. Hong, H. S. Kim, S. J. Shin, Y. H. Park, H. N. Mai, S. M. Oh, K. S. Kim, D. H. Yoo, W. K. Chung, H. Chung, dan M. Moon, "Neuroprotective and anti-inflammatory effects of low–moderate dose ionizing radiation in models of alzheimer's disease," *Int. J. Mol. Sci.*, vol. 21, no. 10, 2020, doi: 10.3390/ijms21103678.
- [28] S. Hwang, H. Jeong, E. H. Hong, H. M. Joo, K. S. Cho, dan S. Y. Nam, "Low-dose ionizing radiation alleviates A β 42-induced cell death via regulating AKT and p38 pathways in Drosophila Alzheimer's disease models," *Biol. Open*, vol. 8, no. 2, hal. 1–9, 2019, doi: 10.1242/bio.036657.
- [29] J. M. Cuttler, E. Abdellah, Y. Goldberg, S. Al-Shamaa, S. P. Symons, S. E. Black, dan M. Freedman, "Low doses of ionizing radiation as a treatment for Alzheimer's Disease: A Pilot Study," *J. Alzheimer's Dis.*, vol. 80, no. 3, hal. 1119–1128, 2021, doi: 10.3233/JAD-200620.
- [30] C. L. Rogers, S. K. Lageman, J. Fontanesi, G. D. Wilson, P. A. Boling, J. P. Karis, M. Sabbagh, M. P. Mehta, dan T. J. Harris, "Low-dose whole brain radiation therapy for Alzheimer's dementia: Results From a Pilot Trial in Humans," *Int. J. Radiat. Oncol.*, no. March, hal. 1–5, 2023, doi: 10.1016/j.ijrobp.2023.03.044.
- [31] M. Goedert dan M. G. Spillantini, "Synucleinopathies," in *Basic Neurochemistry*, Eighth.Oxford: Elsevier Inc, 2012, hal. xxi. doi: 10.1016/b978-0-12-374947-5.00067-5.
- [32] P. C. Wong, A. Savonenko, T. Li, dan D. L. Price, "Neurobiology of Alzheimer's," in *Basic Neurochemistry*, Eighth.Oxford: Elsevier Inc, 2012, hal. xxi. doi: 10.1016/b978-0-12-374947-5.00067-5.
- [33] M. T. Heneka, M. J. Carson, J. El Khoury, G. E. Landreth, F. Brosseron, D. L. Feinstein, A. H. Jacobs, T. Wyss-Coray, J. Vitorica, R. M. Ransohoff, K. Herrup, S. A. Frautschy, B. Finsen, G. C. Brown, A. Verkhratsky, K.



- Yamanaka, J. Koistinaho, E. Latz, A. Halle, *et al.*, “Neuroinflammation in Alzheimer’s disease,” *Lancet Neurol.*, vol. 14, no. 4, hal. 388–405, 2015, doi: 10.1016/S1474-4422(15)70016-5.
- [34] P. Prasanna, S. Rathee, V. Rahul, D. Mandal, M. S. C. Goud, P. Yadav, S. Hawthorne, A. Sharma, P. K. Gupta, S. Ojha, N. K. Jha, C. Villa, dan S. K. Jha, “Microfluidic platforms to unravel mysteries of alzheimer’s disease: How far have we come?,” *Life*, vol. 11, no. 10, hal. 1–24, 2021, doi: 10.3390/life11101022.
- [35] M. S. Hofman dan R. J. Hicks, “How We Read Oncologic FDG PET/CT,” *Cancer Imaging*, vol. 16, no. 1, hal. 1–14, 2016, doi: 10.1186/s40644-016-0091-3.
- [36] A. Vaiserman, J. M. Cuttler, dan Y. Socol, “Low-dose ionizing radiation as a hormetin: experimental observations and therapeutic perspective for age-related disorders,” *Biogerontology*, vol. 5, 2021, doi: 10.1007/s10522-020-09908-5.
- [37] R. K. Kim, M. J. Kim, K. M. Seong, N. Kaushik, Y. Suh, K. C. Yoo, Y. H. Cui, Y. W. Jin, S. Y. Nam, dan S. J. Lee, “Beneficial effects of low dose radiation in response to the oncogenic KRAS induced cellular transformation,” *Sci. Rep.*, vol. 5, no. May, hal. 1–10, 2015, doi: 10.1038/srep15809.
- [38] E. Yang, H. Kim, Y. Choi, H. J. Kim, J. H. Kim, J. Yoon, Y.-S. Seo, dan H. Kim, “Modulation of Neuroinflammation by Low-Dose Radiation Therapy in an Animal Model of Alzheimer’s Disease,” *Int. J. Radiat. Oncol.*, hal. 1–20, Jun 2021, doi: 10.1016/j.ijrobp.2021.06.012.
- [39] L. E. Feinendegen, “Quantification of Adaptive Protection Following Low-dose Irradiation,” *Health Phys.*, vol. 110, no. 3, hal. 276–280, 2016, doi: 10.1097/HP.0000000000000431.
- [40] Y. J. Jeong, Y. Son, H. J. Park, S. J. Oh, J. Y. Choi, Y. G. Ko, dan H. J. Lee, “Therapeutic effects of aripiprazole in the 5xfad alzheimer’s disease mouse model,” *Int. J. Mol. Sci.*, vol. 22, no. 17, 2021, doi: 10.3390/ijms22179374.
- [41] J. S. Kim, S. H. Lee, E.-B. Ko, S. H. Kim, K. W. Sung, C. H. Ji, M. Moon, Y. T. Kwon, dan W. K. Chung, “Synergistic efficacy by combination of AUTOTAC and low dose radiation in Alzheimer’s disease,” *Radiother. Oncol.*, vol. 170, hal. S1620, 2022, doi: [https://doi.org/10.1016/S0167-8140\(22\)03784-7](https://doi.org/10.1016/S0167-8140(22)03784-7).
- [42] S. Kim, H. Chung, H. N. Mai, Y. Nam, S. J. Shin, Y. H. Park, M. J. Chung, J. K. Lee, H. Y. Rhee, G. H. Jahng, Y. Kim, Y. J. Lim, M. Kong, M. Moon, dan W. K. Chung, “Low-dose ionizing radiation modulates microglia phenotypes in the models of Alzheimer’s disease,” *Int. J. Mol. Sci.*, vol. 21, no. 12, hal. 1–18, 2020, doi: 10.3390/ijms21124532.



- [43] N. R. C. (US) and I. of M. (US) C. on S. of the S. of N. Medicine, *Advancing nuclear medicine through innovation*. 2007. doi: 10.17226/11985.
- [44] C. H. Yeong, M. hua Cheng, dan K. H. Ng, "Therapeutic radionuclides in nuclear medicine: Current and future prospects," *J. Zhejiang Univ. Sci. B*, vol. 15, no. 10, hal. 845–863, 2014, doi: 10.1631/jzus.B1400131.
- [45] "Nuclide-S-35decay," *Environmental Health & Safety University of Toronto*. <https://ehs.utoronto.ca/our-services/radiation-safety/nuclide-s-35decay/> (diakses 19 Juli 2023).
- [46] A. M. Esposito dan T. G. Kinzy, *In vivo [³⁵S]-methionine incorporation*, 1 ed., vol. 536. Elsevier Inc., 2014. doi: 10.1016/B978-0-12-420070-8.00005-2.
- [47] C. Xue, T. Y. Lin, D. Chang, dan Z. Guo, "Thioflavin T as an amyloid dye: Fibril quantification, optimal concentration and effect on aggregation," *R. Soc. Open Sci.*, vol. 4, no. 1, 2017, doi: 10.1098/rsos.160696.
- [48] N. Iwakawa, D. Morimoto, E. Walinda, Y. Kawata, M. Shirakawa, dan K. Sugase, "Real-time observation of the interaction between thioflavin T and an amyloid protein by using high-sensitivity Rheo-NMR," *Int. J. Mol. Sci.*, vol. 18, no. 11, hal. 1–8, 2017, doi: 10.3390/ijms18112271.
- [49] "Thioflavin T," *PubChem*. <https://pubchem.ncbi.nlm.nih.gov/compound/Thioflavin-T> (diakses 21 Juni 2021).
- [50] "Safety Data Sheet Thioflavin T ver. 8.2," *Sigma-Aldrich*, 2023. <chrome-extension://oemmnadbldboiebfnladdacbfmadadm/https://www.sigmaaldrich.com/ID/en/sds/SIGMA/T3516> (diakses 19 Juli 2023).
- [51] S. Hatashita, H. Yamasaki, Y. Suzuki, K. Tanaka, D. Wakebe, dan H. Hayakawa, "18F Flutemetamol amyloid-beta PET imaging compared with [¹¹C]PIB across the spectrum of Alzheimer's disease," *Eur. J. Nucl. Med. Mol. Imaging*, vol. 41, no. 2, hal. 290–300, 2014, doi: 10.1007/s00259-013-2564-y.
- [52] M. Koole, D. M. Lewis, C. Buckley, N. Nelissen, M. Vandenbulcke, D. J. Brooks, R. Vandenberghe, dan K. Van Laere, "Whole-body biodistribution and radiation dosimetry of 18F-GE067: A radioligand for in vivo brain amyloid imaging," *J. Nucl. Med.*, vol. 50, no. 5, hal. 818–822, 2009, doi: 10.2967/jnumed.108.060756.
- [53] G. Akamatsu, T. Nishio, K. Adachi, Y. Ikari, dan M. Senda, "Whole-body biodistribution and the influence of body activity on brain kinetic analysis of the 11C-PiB PET scan," *Radiol. Phys. Technol.*, vol. 10, no. 4, hal. 464–474, 2017, doi: 10.1007/s12194-017-0419-0.
- [54] M. Senda, D. J. Brooks, G. Farrar, E. J. Somer, C. L. Paterson, M. Sasaki, dan B. J. McParland, "The clinical safety, biodistribution and internal



- radiation dosimetry of flutemetamol (¹⁸F) injection in healthy Japanese adult volunteers,” *Ann. Nucl. Med.*, vol. 29, no. 7, hal. 627–635, 2015, doi: 10.1007/s12149-015-0986-2.
- [55] N. M. Scheinin, T. K. Tolvanen, I. A. Wilson, E. M. Arponen, K. Å. Någren, dan J. O. Rinne, “Biodistribution and radiation dosimetry of the amyloid imaging agent ¹¹C-PIB in humans,” *J. Nucl. Med.*, vol. 48, no. 1, hal. 128–133, 2007.
- [56] Committee for Medicinal Products for Human Use, “Vizamyl flutemetamol (¹⁸F) Assessment report for an initial marketing authorisation application,” London, 2014. [Daring]. Tersedia pada: www.ema.europa.eu/contact
- [57] W. Sudprasert, O. V. Belyakov, dan S. Tashiro, “Biological and internal dosimetry for radiation medicine: Current status and future perspectives,” *J. Radiat. Res.*, vol. 63, no. 2, hal. 247–254, 2022, doi: 10.1093/jrr/rrab119.
- [58] C. Hindorf, *Nuclear Medicine Physics: A Handbook for Teachers and Students*. 2014. [Daring]. Tersedia pada: https://humanhealth.iaea.org/HHW/MedicalPhysics/e-learning/Nuclear_Medicine_Handbook_slides/Chapter_18_Internal_Dosimetry.pdf
- [59] “Internal Radiation Dosimetry,” *Radiology Key*. <https://radiologykey.com/internal-radiation-dosimetry/> (diakses 10 Juli 2023).
- [60] M. Chauvin, D. Borys, F. Botta, P. Bzowski, J. Dabin, A. M. Denis-Bacelar, A. Desbrée, N. Falzone, B. Q. Lee, A. Mairani, A. Malaroda, G. Mathieu, E. McKay, E. Mora-Ramirez, A. P. Robinson, D. Sarrut, L. Struelens, A. V. Gil, dan M. Bardiès, “OpenDose: Open-access resource for nuclear medicine dosimetry,” *J. Nucl. Med.*, vol. 61, no. 10, hal. 1514–1519, 2020, doi: 10.2967/jnumed.119.240366.
- [61] “Avogadro - Free cross-platform molecular editor.” avogadro.cc (diakses 1 Juli 2023).
- [62] “Educational-Use Only PyMOL Builds,” *Schrodinger*. <https://pymol.org/edu/> (diakses 1 Juli 2023).
- [63] S. Dallakyan dan A. Olson, “PyRx : Python Prescription Virtual Screening Tool.” pyrx.sourceforge.io (diakses 1 Juli 2023).
- [64] T. Lührs, C. Ritter, M. Adrian, D. Riek-Loher, B. Bohrmann, H. Döbeli, D. Schubert, dan R. Riek, “3D structure of Alzheimer’s amyloid- β (1-42) fibrils,” *Proc. Natl. Acad. Sci. U. S. A.*, vol. 102, no. 48, hal. 17342–17347, 2005, doi: 10.1073/pnas.0506723102.
- [65] J. P. Colletier, A. Laganowsky, M. Landau, M. Zhao, A. B. Soriaga, L. Goldschmidt, D. Flot, D. Cascio, M. R. Sawaya, dan D. Eisenberg, “Molecular basis for amyloid- β polymorphism,” *Proc. Natl. Acad. Sci. U. S.*



- A., vol. 108, no. 41, hal. 16938–16943, 2011, doi: 10.1073/pnas.1112600108.
- [66] L. Cerofolini, E. Ravera, S. Bologna, T. Wiglenda, A. Böddrich, B. Purfürst, I. Benilova, M. Korsak, G. Gallo, D. Rizzo, L. Gonnelli, M. Fragai, B. De Strooper, E. E. Wanker, dan C. Luchinat, “Mixing A β (1-40) and A β (1-42) peptides generates unique amyloid fibrils,” *Chem. Commun.*, vol. 56, no. 62, hal. 8830–8833, 2020, doi: 10.1039/d0cc02463e.
- [67] U. Ghosh, K. R. Thurber, W. M. Yau, dan R. Tycko, “Molecular structure of a prevalent amyloid- β fibril polymorph from Alzheimer’s disease brain tissue,” *Proc. Natl. Acad. Sci. U. S. A.*, vol. 118, no. 4, 2021, doi: 10.1073/pnas.2023089118.
- [68] S. Dallakyan dan A. J. Olson, “Small-Molecule Library Screening by Docking with PyRx,” in *Chemical Biology: Methods and Protocols*, 2015, hal. 243–250. doi: 10.1007/978-1-4939-2269-7_19.
- [69] N. M. Hassan, A. A. Alhossary, Y. Mu, dan C. K. Kwoh, “Protein-Ligand Blind Docking Using QuickVina-W with Inter-Process Spatio-Temporal Integration,” *Sci. Rep.*, vol. 7, no. 1, hal. 1–13, 2017, doi: 10.1038/s41598-017-15571-7.
- [70] O. Trott dan A. J. Olson, “AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading,” *J. Comput. Chem.*, vol. 31, hal. 455–461, 2009, doi: 10.1002/jcc.21334.
- [71] S. Stanic dan J. S. Mayadev, “Tolerance of the small bowel to therapeutic irradiation: A focus on late toxicity in patients receiving para-aortic nodal irradiation for gynecologic malignancies,” *Int. J. Gynecol. Cancer*, vol. 23, no. 4, hal. 592–597, 2013, doi: 10.1097/IGC.0b013e318286aa68.
- [72] S. Ansari, M. K. Zope, dan N. Yadav, “A new method for risk factor assessment of organs at risk including conformity index in radiotherapy treatment plan,” *J. Radiother. Pract.*, vol. 20, no. 2, hal. 144–152, 2021, doi: 10.1017/S1460396920000205.

